Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 36635088.
- Also identified by DOI 10.2967/jnumed.122.264946 and PMC identifier 10241017.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first <sup>177</sup>Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. <b>Methods:</b> We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (<i>n</i> = 29), caregivers (<i>n</i> = 14), and clinicians (<i>n</i> = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. <b>Results:</b> This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. <b>Conclusion:</b> The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.
Medical subject headings
- Prostatic Neoplasms